Pre-Black Friday Deal: 75% OFF Active!

Compounded Tirzepatide Online: $99/mo Flat-Rate Care

Accessing compounded tirzepatide online through Losing Weight RX gives eligible patients a licensed clinician evaluation and 503A pharmacy fulfillment at $99/mo flat with $0 membership fees. Pre-Black Friday Special: Dual GLP-1/GIP therapy now $99/mo flat across all doses (was $399/mo). Free 1-2 day delivery & free Zofran® included!

$99/mo (Pre-Black Friday 75% OFF · Was $399) · all-inclusive
No Insurance NeededHSA/FSA EligibleFree Shipping
Compounded Tirzepatide medication vial
Simple Process

How to get tirzepatide prescribed online

From assessment to delivery in as few as 4 days. No office visits required.

Step 1

Complete online assessment

Answer a 5-minute health questionnaire covering your medical history, current medications, and weight loss goals.

Step 2

Provider review within 24 hours

A board-certified U.S. physician evaluates your profile and prescribes tirzepatide if clinically appropriate.

Step 3

Medication shipped to your door

Your prescription is compounded by a licensed 503A pharmacy and cold-shipped express in 3–5 business days.

Why choose tirzepatide for weight loss

Dual-action GLP-1/GIP agonist with superior clinical outcomes.

Dual GLP-1/GIP Action

Tirzepatide activates both GLP-1 and GIP receptors for enhanced appetite suppression and metabolic improvement. Clinical trials show up to 22.5% body weight reduction.

Pre-Black Friday: $99/mo (75% OFF)

Medication, provider consultation, free Zofran®, and free 1-2 day cold-chain shipping included on Pre-Black Friday 75% OFF promo. Flat rate locked across every dose!

Board-Certified Providers

Licensed U.S. physicians prescribe if clinically appropriate. Ongoing clinical support included throughout your treatment journey.

Fast, Discreet Delivery

Custom-compounded by licensed 503A pharmacies. Temperature-controlled cold-chain shipping to your door in 3–5 business days.

The science behind tirzepatide

First-in-class dual agonist backed by the SURMOUNT clinical trial program.

22.5%
Average body weight reduction in SURMOUNT-1 trial
91%
Achieved clinically significant weight loss (≥5%)
2x
Receptor pathways targeted vs. single-action GLP-1s

How tirzepatide works

Tirzepatide is the first dual GLP-1/GIP receptor agonist — a medication that targets two incretin hormone pathways simultaneously for enhanced metabolic benefits.

  • Dual receptor activation targets both GLP-1 and GIP pathways for superior appetite suppression
  • Greater weight loss than single-action GLP-1 medications in head-to-head comparisons
  • Improves insulin sensitivity and blood sugar regulation through complementary mechanisms
  • FDA-approved as Mounjaro® (diabetes) and Zepbound® (weight loss)

Transparent, all-inclusive pricing

No hidden fees. No surprise charges. Everything included.

Black Friday Deal
Advanced Weight Management
Compounded Tirzepatide
$99
per month · Black Friday 83% OFF (Was $299) · All Doses
  • Dual GLP-1/GIP protocol
  • Board-certified provider review
  • Custom compounding by licensed pharmacy
  • Free express cold-chain shipping
  • No membership fees
  • No dose escalation charges
  • HSA/FSA eligible
Get Started

Frequently asked questions about tirzepatide

Compounded tirzepatide contains the same active ingredient as brand-name Mounjaro® and Zepbound®, custom-prepared by a licensed 503A compounding pharmacy for individual patient use when clinically appropriate. Compounded medications are not FDA-approved products.

Tirzepatide activates both GLP-1 and GIP receptors (dual agonist), while semaglutide only activates GLP-1. Clinical trials show tirzepatide produces greater weight loss on average (22.5% vs. 15–17%). However, individual responses vary and your provider can help determine which is right for you.

The SURMOUNT-1 trial showed participants losing up to 22.5% of body weight over 72 weeks — for example, a 250 lb person could lose over 56 lbs. 91% of participants achieved at least 5% weight loss. Individual results vary.

No. Our $99/mo pricing is designed for cash-pay patients. Compare to Zepbound at $299–$449/mo through the manufacturer or Mounjaro at $1,000+/mo without insurance. No prior authorization needed. HSA/FSA accepted.

Similar to semaglutide: nausea, vomiting, diarrhea, and constipation. These typically improve as your body adjusts over the first few weeks. Your provider will guide gradual dose titration to minimize side effects.

Both are highly effective GLP-1 medications. Tirzepatide may produce greater weight loss due to its dual receptor activity but comes at a higher price point ($99 vs. $49/mo). Your provider will review your health profile and goals to recommend the best option.

Active healthy lifestyle

Start your tirzepatide
journey today

Complete your online medical intake now. If clinically appropriate, your compounded tirzepatide will be shipped express to your door. $99/mo, all-inclusive.

Begin Assessment →
Open-Science Pricing & Bioavailability Verification (CC-BY-4.0) Independently benchmarked in our 2026 empirical dataset by the Losing Weight RX Pharmacoeconomics Desk.
Interactive Dataset DOI: 10.5281/zenodo.24139315 Parquet Split 2026 Audit Report

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Compounded Tirzepatide Online: $99/mo Flat-Rate Care is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. (2025). Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. Advances in therapy, 42(10), 5055-5071. https://doi.org/10.1007/s12325-025-03288-3
  2. Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025). Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA health forum, 6(3), e245586. https://doi.org/10.1001/jamahealthforum.2024.5586
  3. Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025). Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. Journal of managed care & specialty pharmacy, 31(5), 441-450. https://doi.org/10.18553/jmcp.2025.31.5.441
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know